Neurodegenerative Disease clinical trials at UCSD
5 in progress, 2 open to eligible people
Transplantation of Human iPS Cell-derived Dopaminergic Progenitors (CT1-DAP001) for Parkinson's Disease (Phase I/II)
open to eligible people ages 40-75
To evaluate the safety and efficacy of transplantation of human induced pluripotent stem cell-derived dopaminergic progenitors, CT1-DAP001, into the corpus striatum in patients with Parkinson's disease
La Jolla, California
PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort
open to eligible people ages 30 years and up
The Parkinson Progression Marker Initiative (PPMI) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest PD, prodromal PD, and healthy controls. The overall goal of PPMI is to identify markers of disease progression for use in clinical trials of therapies to reduce progression of PD disability.
La Jolla, California and other locations
Lu AF82422 in Participants With Multiple System Atrophy
Sorry, in progress, not accepting new patients
To find out the effect of Lu AF82422 on disease progression in participants with multiple system atrophy.
La Jolla, California and other locations
PTC518 in Participants With Huntington's Disease (HD)
Sorry, in progress, not accepting new patients
The primary goal of this study is to evaluate the safety and pharmacodynamic effects of PTC518 compared with placebo in participants with HD.
La Jolla, California and other locations
Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD
Sorry, in progress, not accepting new patients
The purpose of this randomized, double-blind, placebo-controlled study is to assess the efficacy of BIA 28-6156 over placebo in delaying clinical meaningful motor progression over 78 weeks in subjects with Parkinson's disease who have a pathogenic variant in the glucocerebrosidase 1 (GBA1) gene (GBA-PD).
La Jolla, California and other locations
Our lead scientists for Neurodegenerative Disease research studies include Joseph Ciacci, MD Douglas Galasko, MD.
Last updated: